Freeline Therapeutics Holdings plc(FRLN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FRLN Freeline Therapeutics Holdings plc

Halted 12-23 11:25:36 EST

6.48

+0.00

0.00%

High6.48	Low6.48	Vol0.00
Open6.48	D1 Closing6.48	Amplitude0.00%
Mkt Cap28.25M	Tradable Cap11.58M	Total Shares4.36M
T/O36.65K	T/O Rate0.00%	Tradable Shares1.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"FRLN","market":"US","secType":"STK","nameCN":"Freeline Therapeutics Holdings plc","latestPrice":6.48,"timestamp":1708117200000,"preClose":6.48,"halted":3,"volume":0,"delay":0,"floatShares":1787621,"shares":4360133,"eps":-11.496968,"marketStatus":"Halted","change":0,"latestTime":"12-23 11:25:36 EST","open":6.48,"high":6.48,"low":6.48,"amount":36649.8993062,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-11.496968,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1734987600000},"marketStatusCode":2,"adr":0,"adrRate":15,"listingDate":1596772800000,"exchange":"NASDAQ","adjPreClose":6.48,"volumeRatio":0},"requestUrl":"/m/hq/s/FRLN/tweets","defaultTab":"tweets","newsList":[{"id":"2412898175","title":"Acquisition of Freeline by Syncona Becomes Effective","url":"https://stock-news.laohu8.com/highlight/detail?id=2412898175","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2412898175?lang=en_us&edition=fundamental","pubTime":"2024-02-20 20:00","pubTimestamp":1708430400,"startTime":"0","endTime":"0","summary":"LONDON, Feb. 20, 2024  -- Freeline Therapeutics Holdings plc   and Syncona Ltd  today announced that, in connection with Syncona’s acquisition of Freeline by way of a scheme of arrangement , the Scheme has been sanctioned by the Court and the court order (together with a copy of the scheme circular published by Freeline on January 18, 2024 (the “Scheme Circular”) has been delivered to the Registrar of Companies. Accordingly, the Scheme has become Effective in accordance with its terms and the entire issued share capital of Freeline is now owned or controlled by Syncona Portfolio Limited.Next steps and timetableScheme Shareholders on the register of shareholders of Freeline at 6.00 p.m. GMT on February 19, 2024 will be entitled to receive $0.433333 in cash for each Scheme Share held or $6.50 in cash per American Depositary Share of Freeline .Board changesAs the Scheme has now become Effective, Julia Gregory, Martin Andrews, Jeffrey Chodakewitz, Colin Love and Paul Schneider have stepped","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7Of9V4f2ltFy4HW65CUhA--~B/aD02Njt3PTMwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d1337331f3e629baac75a398be0b8a4f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7Of9V4f2ltFy4HW65CUhA--~B/aD02Njt3PTMwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d1337331f3e629baac75a398be0b8a4f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acquisition-freeline-syncona-becomes-effective-120000970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FRLN","BK4139"],"gpt_icon":0},{"id":"2411824191","title":"Press Release: Freeline Shareholders Approve Acquisition by Syncona","url":"https://stock-news.laohu8.com/highlight/detail?id=2411824191","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2411824191?lang=en_us&edition=fundamental","pubTime":"2024-02-13 01:00","pubTimestamp":1707757200,"startTime":"0","endTime":"0","summary":"LONDON, Feb. 12, 2024  -- Freeline Therapeutics Holdings plc   and Syncona Ltd  today announced that Freeline's shareholders have approved the proposal for Bidco 1354 Limited , a wholly owned subsidiary of Syncona Portfolio Limited , to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share  in cash . As previously announced, Freeline and Bidco entered into an implementation agreement on November 22, 2023 to implement the Acquisition by means of a scheme of arrangement pursuant to Part 26 of the UK Companies Act 2006 .Voting results of the Court Meeting and General Meeting. Chris Hollowood, CEO of Syncona Investment Management Limited, said: \"We are delighted our proposal to acquire Freeline has been approved by the required majority of Freeline shareholders. We continue to be encouraged by the data published from its FLT201 Gaucher programme. The challenging market conditions impacting the biotech sector have presented a differe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FRLN","BK4139"],"gpt_icon":0},{"id":"2403229380","title":"Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2403229380","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2403229380?lang=en_us&edition=fundamental","pubTime":"2024-01-12 22:31","pubTimestamp":1705069860,"startTime":"0","endTime":"0","summary":"Shares of Amicus Therapeutics, Inc. FOLD have rallied 27.9% in the past three months compared with the industry’s increase of 10.7%.In late September 2023, the FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease  in adults who weigh more than 40 kg and are not improving on their current enzyme replacement therapy.The approval for Pombiliti + Opfolda in the United States is a huge boost and provides a significant commercial opportunity for Amicus in 2024. This could have been one of the factors driving the stock’s rise in the said time frame.Earlier in 2023, Pombiliti + Opfolda was approved in Europe, including the United Kingdom, for treating LOPD in adults.Amicus’ lead drug, Galafold , is the first and only approved oral medicine for patients living with Fabry disease, having amenable genetic variants. The drug has shown solid uptake since its launch.CytomX Therapeutics beat estimates in three of the last four quarters while missing the same","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VTpWEp9iphTX3xsYcMogbg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VTpWEp9iphTX3xsYcMogbg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amicus-fold-stock-rises-more-143100573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065170008.USD","LU2065169927.USD","FOLD","FRLN","LU2065171311.SGD","CTMX","LU2065171402.SGD","BK4139","PBYI"],"gpt_icon":0},{"id":"2402477053","title":"Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2402477053","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2402477053?lang=en_us&edition=fundamental","pubTime":"2024-01-11 22:34","pubTimestamp":1704983640,"startTime":"0","endTime":"0","summary":"Shares of Amarin Corporation plc AMRN surged 32.8% on Jan 10 after the company announced robust preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a share repurchase program of up to $50 million.Amarin’s top line currently comprises product revenues from Vascepa/Vazkepa , as well as licensing and royalty revenues.As of the end of 2023, Amarin had approximately $321 million in cash and investments. The company ended the year with a positive cash flow of almost $10 million.Some other top-ranked stocks in the healthcare sector are Stoke Therapeutics, Inc. STOK, Freeline Therapeutics Holdings plc FRLN and Puma Biotechnology, Inc. PBYI, each sporting a Zacks Rank #1  at present. You can seethe complete list of today’s Zacks #1 Rank stocks here.In the past 60 days, estimates for Stoke Therapeutics’ 2024 loss per share have narrowed from $2.66 to $2.50. In the past year, shares of STOK have plunged 49.1%.Stoke Therapeutics beat estimates in three","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amarin-amrn-stock-rises-stellar-143400690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBYI","AMRN","STOK","BK4139","TG","FRLN","BK4153","BK4090"],"gpt_icon":0},{"id":"2402269476","title":"Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2402269476","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2402269476?lang=en_us&edition=fundamental","pubTime":"2024-01-11 21:59","pubTimestamp":1704981540,"startTime":"0","endTime":"0","summary":"Mirati Therapeutics, Inc. MRTX announced that the European Commission  has granted conditional marketing authorization to Krazati  for the treatment of adult patients with previously-treated KRASG12C-mutated advanced non-small cell lung cancer .The EC’s conditional marketing nod for Krazati, a KRAS G12C inhibitor, is valid in all 27 EU member states.The approval by EC was expected as, in November 2023, the European Medicine Agency's Committee for Medicinal Products for Human Use  recommended approving Krazati.The CHMP had initially issued a negative opinion in July 2023, stating that the Krazati marketing authorization application  did not fulfill certain requirements for conditional approval. The committee had claimed that the data supporting the MAA was not comprehensive and there were uncertainties about how well the drug worked.Shares of Mirati have rallied 38.3% in the past year against the industry’s decline of 11.5%.In the past 60 days, estimates for Puma Biotechnology’s 2024 ea","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KEj1lCkxRqndrrMrF3m.HA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KEj1lCkxRqndrrMrF3m.HA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirati-mrtx-gets-eu-nod-135900894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505868.SGD","IE0002141913.USD","IE00B2B36J28.USD","CHMP","LU0321505439.SGD","BK4087","IE0009355771.USD","BMY","IE00BJJMRZ35.SGD","LU1670710588.SGD","LU1261432733.SGD","BK4156","LU1670710661.SGD","LU2242646821.SGD","BK4532","LU1074936037.SGD","BK4139","LU1585245621.USD","IE00BJT1NW94.SGD","LU0868494617.USD","BK4559","IE00BFTCPJ56.SGD","EC","LU1670711123.USD","LU0114720955.EUR","BK4007","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","LU0061475181.USD","LU1989771016.USD","LU2360032135.SGD","PBYI","LU1430594728.SGD","LU1571399168.USD","LU1032466523.USD","FRLN","LU0456855351.SGD","LU0237698245.USD","LU1291159041.SGD","MRTX","BK4534","BK4201","IE00BSNM7G36.USD","BK4581","LU2125154935.USD","EU","LU1670711040.USD","LU2242652126.USD","BK4588"],"gpt_icon":0},{"id":"2402948774","title":"SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2402948774","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2402948774?lang=en_us&edition=fundamental","pubTime":"2024-01-11 00:30","pubTimestamp":1704904200,"startTime":"0","endTime":"0","summary":"The Fast Track designation from the FDA facilitates rapid development and expedites the review of candidates that are being developed to treat serious conditions and have the potential to address unmet medical needs.The Fast Track tag is likely to expedite the development path for SLS009 and help in a faster regulatory filing for the candidate in r/r AML in the United States.The FDA has already granted an Orphan Drug designation to SLS009 for r/r AML.Shares of SELLAS have plunged 79.2% in the past year compared with the industry’s decline of 11.4%.Concurrently, the company announced initial positive top-line data from the 45 mg  dose cohort of a phase IIa study on SLS009. A total of nine patients were enrolled in the 45 mg cohort.In the study, treatment with the 45mg dose of SLS009 in combination with aza/ven demonstrated anti-leukemic effects with a favorable safety profile in AML patients who are resistant to venetoclax combination therapies.In the past 60 days, estimates for Sarepta","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OqpBwYnlazUrZRs4ONCSFw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OqpBwYnlazUrZRs4ONCSFw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sellas-sls-rises-fda-fast-163000372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IE00BJT1NW94.SGD","CR","FAST","BK4161","FRLN","SRPT","PBYI","BK4585","IE0002141913.USD","IE00B2B36J28.USD","SLS","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2387846061","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX) and Freeline Therapeutics Holdings (FRLN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2387846061","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2387846061?lang=en_us&edition=fundamental","pubTime":"2023-11-30 10:10","pubTimestamp":1701310205,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Argenx Se (ARGX – Research Report) and Freeline Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-argenx-se-argx-and-freeline-therapeutics-holdings-frln?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-argenx-se-argx-and-freeline-therapeutics-holdings-frln?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","HCSG","FRLN","BK4137","BK4139","ARGX","BK4505","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2385678737","title":"Freeline (FRLN) Shares Rise on Merger Agreement With Syncona","url":"https://stock-news.laohu8.com/highlight/detail?id=2385678737","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2385678737?lang=en_us&edition=fundamental","pubTime":"2023-11-24 00:03","pubTimestamp":1700755380,"startTime":"0","endTime":"0","summary":"Freeline Therapeutics Holdings plc FRLN, a clinical-stage biotechnology company, announced that it has entered into a definitive agreement with United Kingdom-based portfolio company Syncona Ltd. Per the deal, Freeline is set to be acquired by Syncona in an all-cash transaction.The above transaction is expected to be closed in the first quarter of 2024, subject to approval by Freeline’s minority shareholders. Shares of Freeline were up 10.2% on Nov 22 following the announcement of the news.Per the acquisition agreement, Syncona will acquire all shares of Freeline for $6.50 per American Depositary Share  that it currently does not own. The price offered by Syncona represents a 51% premium over the closing price of Freeline’s shares as of Oct 18 and values the latter’s entire issued share capital at approximately $28.3 million.In the past 60 days, Ligand Pharmaceuticals’ earnings per share estimates for 2023 have improved from $4.98 to $5.33. During the same period,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/freeline-frln-shares-rise-merger-160300908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBYI","LGND","BK4007","BK4139","FRLN","CTMX"],"gpt_icon":0},{"id":"2385663525","title":"Freeline Therapeutics Shares Rise on Takeover by Syncona","url":"https://stock-news.laohu8.com/highlight/detail?id=2385663525","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2385663525?lang=en_us&edition=fundamental","pubTime":"2023-11-22 23:19","pubTimestamp":1700666340,"startTime":"0","endTime":"0","summary":"Freeline Therapeutics Holdings's American depositary shares rose more than 11% on Wednesday after the company agreed to be taken private by majority shareholder Syncona.Freeline ADSs were recently changing hands at $6.40.  The shares are down about 10% for the year.The clinical-stage biotechnology company said Syncona, which already owns about 58% of Freeline, will pay $6.50 each for the remaining ADSs, a 12% premium to Tuesday's closing price and more than 50% above its closing price on Oct. 17, before Syncona revealed that is had made an initial offer of $5 per ADS.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FRLN"],"gpt_icon":0},{"id":"2385659066","title":"Freeline Therapeutics to be acquired by Syncona for $28.3M in cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2385659066","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2385659066?lang=en_us&edition=fundamental","pubTime":"2023-11-22 20:51","pubTimestamp":1700657472,"startTime":"0","endTime":"0","summary":"U.K.-based biotech Freeline Therapeutics  announced Wednesday that the British investment firm Syncona Ltd. has agreed to acquire it for a total equity value of ~$28.3M in an all-cash transaction. Per the terms, Syncona will buy the shares it doesn’t currently own in Freeline  for $6.50 per American Depositary Share , implying a 51% premium over its closing price when the FTSE250 healthcare company initiated the buyout proposal on Oct. 18.  Syncona will establish a new portfolio company to proceed with the deal, which is expected to close in Q1 2024, subject to the approval of FRLN’s minority investors. Concurrently, Syncona has agreed to provide Freeline  with up to $15M in convertible debt financing, which the company intends to use for operations, including studies for its gene therapy candidate FLT201 for Gaucher disease through the close of the transaction.    More on Freeline Therapeutics  Freeline gains on non-binding buyout offer from Syncona Freeline posts early data for gene ","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4039524-freeline-therapeutics-28m-buyout-deal-syncona","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","FRLN"],"gpt_icon":0},{"id":"2385165997","title":"Freeline Therapeutics Agrees to Buyout by Syncona","url":"https://stock-news.laohu8.com/highlight/detail?id=2385165997","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2385165997?lang=en_us&edition=fundamental","pubTime":"2023-11-22 20:46","pubTimestamp":1700657160,"startTime":"0","endTime":"0","summary":"Freeline Therapeutics Holdings has agreed to be acquired by majority shareholder Syncona in a deal that values the clinical-stage biotechnology company at about $28.3 million.Freeline on Wednesday said a newly established portfolio company of life-science investor Syncona will pay $6.50 apiece for the Freeline American depositary shares Syncona doesn't already own.The deal represents a 12% premium to Tuesday's closing price of $5.78 for Freeline and a more than 50% premium to the U.K. company's closing price on Oct. 17, before Syncona unveiled an initial bid of $5 per ADS.Syncona currently owns nearly 58% of Freeline, which said it expects the takeover to close in the first quarter of 2024.Trading in Freeline ADSs was halted premarket Wednesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FRLN"],"gpt_icon":0},{"id":"2385656208","title":"BRIEF-Syncona To Acquire Freeline Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2385656208","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2385656208?lang=en_us&edition=fundamental","pubTime":"2023-11-22 20:31","pubTimestamp":1700656286,"startTime":"0","endTime":"0","summary":"Nov 22  - Freeline Therapeutics Holdings PLC :   * SYNCONA TO ACQUIRE FREELINE THERAPEUTICS   * FREELINE THERAPEUTICS HOLDINGS PLC - FREELINE SHAREHOLDERS TO RECEIVE $6.50 PER AMERICAN DEPOSITARY SHARESource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FRLN"],"gpt_icon":0},{"id":"2385659132","title":"Syncona to Acquire Freeline Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2385659132","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2385659132?lang=en_us&edition=fundamental","pubTime":"2023-11-22 20:30","pubTimestamp":1700656200,"startTime":"0","endTime":"0","summary":"Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial proposal on October 18, in an all-cash transaction. Based on extensive evaluation of available strategic and financing options, Freeline’s independent directors unanimously recommend transaction as best value for shareholders. Syncona to provide $15 million in convertible debt financing to cover Freeline’s near-term capital needs and support ongoing advancement of its programs. In conjunction with the agreement, Syncona is committing to provide Freeline with up to $15 million in secured convertible debt financing to support operations and continued advancement of FLT201, its gene therapy candidate in Gaucher disease, through completion of the transaction.“Our goal at Freeline is to bring life-changing gene therapies to people with chronic debilitating diseases, starting with FLT201, our highly differentiated AAV gene therapy candidate for Gau","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7Of9V4f2ltFy4HW65CUhA--~B/aD02Njt3PTMwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d1337331f3e629baac75a398be0b8a4f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7Of9V4f2ltFy4HW65CUhA--~B/aD02Njt3PTMwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d1337331f3e629baac75a398be0b8a4f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/syncona-acquire-freeline-therapeutics-123000116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FRLN","BK4139"],"gpt_icon":0},{"id":"2382754164","title":"ADRs End Higher, Yoshitsu Co. Ltd. Climbs 19.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2382754164","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2382754164?lang=en_us&edition=fundamental","pubTime":"2023-11-11 05:41","pubTimestamp":1699652460,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.International stocks trading in New York closed higher Friday as the S&P/BNY Mellon index of American depositary receipts rose 1.4% to 154.47.The European index added 0.7% to 149.99. The Asian index increased 2.5% to 177.89. The Latin American index rose 1.3% to 201.04, while the emerging-markets index gained 2.4% to 288.87.Japan's Yoshitsu Co. Ltd. was the biggest leader during the session, jumping 19.2% to 62 cents. Hong Kong-based uCloudlink Group Inc. rose 16.4% to $2.27. DoubleDown Interactive Co. Ltd., which is based in Korea, rounded out the top three leaders, rising 8.6% to $9.43.Bionomics Ltd., based in Australia, posted the largest decline, plummeting 23.4% to $1.74, followed by shares of U.K.'s Freeline Therapeutics Holdings PLC, which fell 19.1% to $4.25. Shares of China-based Fresh2 Group Ltd. tumbled 18.0% to $1.02.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","LU1969619763.USD","TKLF","LU1820825898.SGD","LU1997245094.SGD","BK0012","BK0187","601318","BK0032","LU1146622755.USD","LU0326950275.SGD","SG9999002463.SGD","BK0207","LU0405327494.USD","LU2328871848.SGD","LU0405327148.USD","BK0070","BK4085","LU1580142542.USD","BK0028","DDI","BK0196","BK4139","BK4200","BK0188","BK4132","LU1781817850.SGD","FRLN","LU1064131003.USD","LU1655091616.SGD","LU2148510915.USD","LU1064130708.USD","LU0039217434.USD","BK0183","FRES","UCL","BNOX","LU1997245177.USD"],"gpt_icon":0},{"id":"2378093986","title":"BRIEF-Freeline Presents Positive New Data From Phase 1/2 GALILEO-1 Trial Of FLT201","url":"https://stock-news.laohu8.com/highlight/detail?id=2378093986","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2378093986?lang=en_us&edition=fundamental","pubTime":"2023-10-25 14:04","pubTimestamp":1698213845,"startTime":"0","endTime":"0","summary":"Oct 25  - Freeline Therapeutics Holdings Plc :   * FREELINE PRESENTS POSITIVE NEW DATA FROM PHASE 1/2 GALILEO-1 TRIAL OF FLT201, ITS NOVEL GENE THERAPY CANDIDATE, IN GAUCHER DISEASE AT ESGCT 30TH ANNUAL CONGRESS   * FLT201 CONTINUES TO BE WELL-TOLERATED, WITH NO SERIOUS ADVERSE EVENTSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FRLN"],"gpt_icon":0},{"id":"2376860284","title":"Here's Why We're A Bit Worried About Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2376860284","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2376860284?lang=en_us&edition=fundamental","pubTime":"2023-10-19 18:39","pubTimestamp":1697711992,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.Given this risk, we thought we'd take a look at whether Freeline Therapeutics Holdings  shareholders should be worried about its cash burn. In this article, we define cash burn as its annual  free cash flow, which is the amount of money a company spends each year to fund its growth. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.See our latest analysis for Freeline Therapeutics Holdings. When Might Freeline Therapeutics Holdings Run Out Of Money?Freeline Therapeutics Holdings has a market capitalisation of US$21m and burnt t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-bit-worried-103952701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","FRLN"],"gpt_icon":0},{"id":"2376441745","title":"Freeline gains on non-binding buyout offer from Syncona","url":"https://stock-news.laohu8.com/highlight/detail?id=2376441745","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2376441745?lang=en_us&edition=fundamental","pubTime":"2023-10-19 00:10","pubTimestamp":1697645420,"startTime":"0","endTime":"0","summary":"Freeline Therapeutics  added ~13% on Wednesday after its majority shareholder Syncona Portfolio Limited disclosed a non-binding proposal to acquire the clinical-stage biotech for $5 per ADS in an all-cash deal. The U.K.-based biotech said its board of directors has appointed a special panel of independent directors to evaluate Syncona’s bid and other strategic and financing opportunities. The company has engaged Leerink Partners LLC to deal with these initiatives.  Freeline Therapeutics  made its public debut in August 2020, raising $158.8M in gross proceeds. Shares of the gene therapy developer surged in March 2022 after Guernsey-based Syncona disclosed a ~63% stake in the company through a 13-D filing.  In April, the company increased the ratio between ADS and ordinary shares in a bid to regain compliance with the Nasdaq minimum bid price requirement.    More on Freeline Therapeutics  Freeline Therapeutics Holdings plc  Q2 2023 Earnings Call Transcript Freeline posts early data for g","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4021620-freeline-stock-gains-syncona-buyout-offer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","FRLN"],"gpt_icon":0},{"id":"2376153274","title":"BRIEF-Syncona Portfolio Ltd Submitted Non-Binding Proposal To Freeline Therapeutics Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2376153274","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2376153274?lang=en_us&edition=fundamental","pubTime":"2023-10-18 18:41","pubTimestamp":1697625712,"startTime":"0","endTime":"0","summary":"Oct 18  - Freeline Therapeutics Holdings PLC :   * SYNCONA PORTFOLIO LTD SAYS ON OCT 17, SUBMITTED NON-BINDING PROPOSAL TO FREELINE THERAPEUTICS HOLDINGS - SEC FILING   * SYNCONA PORTFOLIO LTD SAYS TO ACQUIRE ALL OF OUTSTANDING ORDINARY SHARES OF FREELINE THERAPEUTICS, NOT CURRENTLY OWNED BY SYNCONA AND AFFILIATES   * SYNCONA PORTFOLIO - INTENDS TO ENGAGE IN DISCUSSIONS WITH FREELINE THERAPEUTICS AND REPRESENTATIVES CONCERNING NON-BINDING PROPOSALSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FRLN"],"gpt_icon":0},{"id":"2376413747","title":"Syncona Seeks to Buy Remaining Shares of Freeline Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2376413747","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2376413747?lang=en_us&edition=fundamental","pubTime":"2023-10-18 18:33","pubTimestamp":1697625180,"startTime":"0","endTime":"0","summary":"Syncona that its investment manager has submitted a proposal to buy the shares of Freeline Therapeutics Holdings that it doesn't already own, and plans to start talks with the company over a potential deal.The U.K. healthcare company said Wednesday that it is offering to pay $5.00 for each American Depositary Share of Freeline, a 20% premium over the volume weighted average price of $4.16 between Oct. 4 and Oct. 16.Syncona, which currently owns approximately 57.9% of Freeline, said there isn't a guarantee that any deal will be agreed.Freeline is focused on its FLT201 gene therapy program for the treatment of Gaucher disease, a debilitating condition.Syncona shares at 1030 GMT were up 0.20 pence, or 0.2%, at 126.20 pence.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FRLN","BK4139"],"gpt_icon":0},{"id":"2375864118","title":"Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2375864118","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2375864118?lang=en_us&edition=fundamental","pubTime":"2023-10-16 19:00","pubTimestamp":1697454000,"startTime":"0","endTime":"0","summary":"LONDON, Oct. 16, 2023  -- Freeline Therapeutics Holdings plc today announced that it will present new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus  gene therapy candidate, in patients with Gaucher disease Type 1 at the European Society of Gene & Cell Therapy  30th Annual Congress being held October 24-27, 2023 in Brussels, Belgium.About FLT201 FLT201 is an adeno-associated virus  gene therapy candidate that is currently being investigated in the Phase 1/2 GALILEO-1 clinical trial in adults with Gaucher disease Type 1. FLT201 is designed to generate durable increases in glucocerebrosidase  and reduce the accumulation of harmful substrates, with the aim of providing a one-time treatment that can stop disease progression, improve outcomes, and free people from lifelong treatment. FLT201 uses Freeline’s proprietary AAVS3 capsid to introduce a novel transgene into liver cells to produce a rationally engineered GCase variant. In preclinical s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ShwT3gnOr4jpRSMvoxmBEA--~B/aD0xNDI7dz02NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2fcff3b8cb63d69e8a620ef79c356f6c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ShwT3gnOr4jpRSMvoxmBEA--~B/aD0xNDI7dz02NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2fcff3b8cb63d69e8a620ef79c356f6c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/freeline-present-clinical-data-flt201-110000511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","FRLN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.freeline.life","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0.0125},{"period":"ytd","weight":0.0173}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.035501},{"month":2,"riseRate":0.25,"avgChangeRate":-0.112462},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.072454},{"month":4,"riseRate":0,"avgChangeRate":-0.181655},{"month":5,"riseRate":0,"avgChangeRate":-0.219641},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.033729},{"month":7,"riseRate":0.666667,"avgChangeRate":0.005964},{"month":8,"riseRate":0,"avgChangeRate":-0.09263},{"month":9,"riseRate":0.25,"avgChangeRate":-0.022304},{"month":10,"riseRate":0.75,"avgChangeRate":0.057144},{"month":11,"riseRate":0.25,"avgChangeRate":-0.049322},{"month":12,"riseRate":0.5,"avgChangeRate":-0.06151}],"exchange":"NASDAQ","name":"Freeline Therapeutics Holdings plc","nameEN":"Freeline Therapeutics Holdings plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Freeline Therapeutics Holdings plc(FRLN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Freeline Therapeutics Holdings plc(FRLN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Freeline Therapeutics Holdings plc,FRLN,Freeline Therapeutics Holdings plc股票,Freeline Therapeutics Holdings plc股票老虎,Freeline Therapeutics Holdings plc股票老虎国际,Freeline Therapeutics Holdings plc行情,Freeline Therapeutics Holdings plc股票行情,Freeline Therapeutics Holdings plc股价,Freeline Therapeutics Holdings plc股市,Freeline Therapeutics Holdings plc股票价格,Freeline Therapeutics Holdings plc股票交易,Freeline Therapeutics Holdings plc股票购买,Freeline Therapeutics Holdings plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Freeline Therapeutics Holdings plc(FRLN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Freeline Therapeutics Holdings plc(FRLN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction